Bicara Therapeutics Inc (BCAX)
Bicara Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing bifunctional therapies for solid tumors. Its lead candidate, ficerafusp alfa, is designed as a bifunctional antibody that brings together an epidermal growth factor receptor-directed monoclonal antibody with human transforming growth factor beta activity for use in solid tumor treatment. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics common stock is listed on the NASDAQ under the symbol BCAX.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-BCAX
|
$16.98
|
-25.0% Downside
|
Overvalued
|
$34.54
|
52.6% Upside
|
Bargain
|
Fair
|
0.0%
|
November 17, 2026
|
3.2x
|
1.498 B
|
1.002 B
|
0.1%
|
55.8%
|
19.1
|
73.0%
|
